Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III, Multicenter, Randomized, Open-Label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as An Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE
A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9?Engineered T Cells CTX110 in Subjects with Relapsed or Refractory B-Cell Malignancies
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT04203316
Principal Investigator:
Kevin Ginn
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors
Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients with Renal Cell Carcinoma
Selective Use of Observation After Lumpectomy and Sentinel Lymph Node Biopsy in Her-2 Positive Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations A Pediatric MATCH Treatment Trial
Study Type: Treatment
Phase: II
NCTID: NCT03210714
Principal Investigator:
Kevin Ginn
Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502
Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Study Type: Treatment
Phase: II
NCTID: NCT02978625
Principal Investigator:
Benjamin Powers